257 related articles for article (PubMed ID: 23643839)
21. [The Relationship Between GSK-3 and Mental Disorders].
Yang J; Li JF; Zhao L
Sheng Li Ke Xue Jin Zhan; 2015 Aug; 46(4):250-4. PubMed ID: 26669074
[TBL] [Abstract][Full Text] [Related]
22. Glycogen synthase kinase-3 and mammalian target of rapamycin pathways contribute to DNA synthesis, cell cycle progression, and proliferation in human islets.
Liu H; Remedi MS; Pappan KL; Kwon G; Rohatgi N; Marshall CA; McDaniel ML
Diabetes; 2009 Mar; 58(3):663-72. PubMed ID: 19073772
[TBL] [Abstract][Full Text] [Related]
23. Glycogen synthase kinase 3: a key regulator of cellular fate.
Forde JE; Dale TC
Cell Mol Life Sci; 2007 Aug; 64(15):1930-44. PubMed ID: 17530463
[TBL] [Abstract][Full Text] [Related]
24. Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells.
McCubrey JA; Fitzgerald TL; Yang LV; Lertpiriyapong K; Steelman LS; Abrams SL; Montalto G; Cervello M; Neri LM; Cocco L; Martelli AM; Laidler P; Dulińska-Litewka J; Rakus D; Gizak A; Nicoletti F; Falzone L; Candido S; Libra M
Oncotarget; 2017 Feb; 8(8):14221-14250. PubMed ID: 27999207
[TBL] [Abstract][Full Text] [Related]
25. Glycogen synthase kinase-3 as drug target: from wallflower to center of attention.
Van Wauwe J; Haefner B
Drug News Perspect; 2003 Nov; 16(9):557-65. PubMed ID: 14702136
[TBL] [Abstract][Full Text] [Related]
26. Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of Type 2 diabetes.
MacAulay K; Woodgett JR
Expert Opin Ther Targets; 2008 Oct; 12(10):1265-74. PubMed ID: 18781825
[TBL] [Abstract][Full Text] [Related]
27. Role of Glycogen Synthase Kinase-3 in Interferon-γ-Mediated Immune Hepatitis.
Chen CL; Tseng PC; Satria RD; Nguyen TT; Tsai CC; Lin CF
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563060
[TBL] [Abstract][Full Text] [Related]
28. Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging.
Pandey MK; DeGrado TR
Theranostics; 2016; 6(4):571-93. PubMed ID: 26941849
[TBL] [Abstract][Full Text] [Related]
29. Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.
McCubrey JA; Steelman LS; Bertrand FE; Davis NM; Abrams SL; Montalto G; D'Assoro AB; Libra M; Nicoletti F; Maestro R; Basecke J; Cocco L; Cervello M; Martelli AM
Leukemia; 2014 Jan; 28(1):15-33. PubMed ID: 23778311
[TBL] [Abstract][Full Text] [Related]
30. Glycogen synthase kinase-3 inhibitor as a multi-targeting anti-rheumatoid drug.
Arioka M; Takahashi-Yanaga F
Biochem Pharmacol; 2019 Jul; 165():207-213. PubMed ID: 30776323
[TBL] [Abstract][Full Text] [Related]
31. GSK-3 as potential target for therapeutic intervention in cancer.
McCubrey JA; Steelman LS; Bertrand FE; Davis NM; Sokolosky M; Abrams SL; Montalto G; D'Assoro AB; Libra M; Nicoletti F; Maestro R; Basecke J; Rakus D; Gizak A; Demidenko ZN; Cocco L; Martelli AM; Cervello M
Oncotarget; 2014 May; 5(10):2881-911. PubMed ID: 24931005
[TBL] [Abstract][Full Text] [Related]
32. Anti-inflammatory Potential of GSK-3 Inhibitors.
Kandar CC; Sen D; Maity A
Curr Drug Targets; 2021; 22(13):1464-1476. PubMed ID: 33461462
[TBL] [Abstract][Full Text] [Related]
33. Glycogen synthase kinase-3 in insulin and Wnt signalling: a double-edged sword?
Patel S; Doble B; Woodgett JR
Biochem Soc Trans; 2004 Nov; 32(Pt 5):803-8. PubMed ID: 15494020
[TBL] [Abstract][Full Text] [Related]
34. The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases.
Amar S; Belmaker RH; Agam G
Curr Pharm Des; 2011; 17(22):2264-77. PubMed ID: 21736545
[TBL] [Abstract][Full Text] [Related]
35. Glycogen synthase kinase-3: A potential target for diabetes.
Teli DM; Gajjar AK
Bioorg Med Chem; 2023 Sep; 92():117406. PubMed ID: 37536264
[TBL] [Abstract][Full Text] [Related]
36. GSK-3 inhibitors and insulin receptor signaling in health, disease, and therapeutics.
Wada A
Front Biosci (Landmark Ed); 2009 Jan; 14(4):1558-70. PubMed ID: 19273146
[TBL] [Abstract][Full Text] [Related]
37. Glycogen synthase kinase-3 signaling in cellular and behavioral responses to psychostimulant drugs.
Barr JL; Unterwald EM
Biochim Biophys Acta Mol Cell Res; 2020 Sep; 1867(9):118746. PubMed ID: 32454064
[TBL] [Abstract][Full Text] [Related]
38. Substrate competitive GSK-3 inhibitors - strategy and implications.
Eldar-Finkelman H; Licht-Murava A; Pietrokovski S; Eisenstein M
Biochim Biophys Acta; 2010 Mar; 1804(3):598-603. PubMed ID: 19770076
[TBL] [Abstract][Full Text] [Related]
39. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders.
Gould TD; Picchini AM; Einat H; Manji HK
Curr Drug Targets; 2006 Nov; 7(11):1399-409. PubMed ID: 17100580
[TBL] [Abstract][Full Text] [Related]
40. Glycogen synthase kinase-3 beta; a new target in pancreatic cancer?
Garcea G; Manson MM; Neal CP; Pattenden CJ; Sutton CD; Dennison AR; Berry DP
Curr Cancer Drug Targets; 2007 May; 7(3):209-15. PubMed ID: 17504118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
